Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.80
Bid: 19.00
Ask: 20.40
Change: -4.80 (-19.59%)
Spread: 1.40 (7.368%)
Open: 22.60
High: 22.60
Low: 20.80
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CORRECTION: Director/PDMR's Dealing

5 Jun 2020 09:02

RNS Number : 1047P
Oncimmune Holdings PLC
05 June 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

CORRECTION: Director/PDMR's Dealing

 

The Director/PDMR Dealing announcement released this morning has been amended as follows: the weighted average price paid by Meinhard and Tatiana Schmidt has been corrected to £1.185 and the date that the Company was notified of dealings by the Director/PDMRs was 4 June 2020. All other details remain the same. The full amended text is shown below.

 

Director/PDMR's Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, was informed that, on 4 June 2020, dealings in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by the following Director / PDMRs had occurred:

 

- Meinhard Schmidt, Non-Executive Chairman, together with his wife and PCA, Tatiana Schmidt, acquired in aggregate 13,000 Ordinary Shares at a weighted average price of £1.185 per share

 

- Tim Bunting, Non-Executive Director, acquired 150,000 Ordinary Shares at a weighted average price of £1.192 per share

 

- Adam Hill, Chief Executive Officer, acquired 8,481 Ordinary Shares at a price of £1.179 per share

 

- Matthew Hall, Chief Financial Officer, acquired 1,272 Ordinary Shares at a price of £1.179 per share

 

- Ron Kirschner, General Counsel and Company Secretary, acquired 1,652 Ordinary Shares at a price of £1.204 per share

 

 

Director/PDMR/ PCA

No. of Ordinary Shares acquired

Resulting interest

Resulting % holding

Meinhard Schmidt / Tatiana Schmidt

13,000

31,000

0.05%

Tim Bunting

150,000

2,956,717

4.7%

Adam Hill

8,481

40,913

0.06%

Matthew Hall

1,272

11,935

0.02%

Ron Kirschner

1,652

1,652

0.003%

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Meinhard Schmidt / Tatiana Schmidt

2

 

Reason for the notification

a)

 

Position/status

 

Non-executive Chairman / PCA

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£1.17

8,000

 

 

 

£1.21

5,000

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

13,000 shares

Weighted average price of £1.185

 

 

- Price

 

 

 

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Timothy Bunting

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£1.195

60,000

 

 

 

£1.19

90,000

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

150,000 shares

Weighted average price of £1.192

 

 

- Price

 

 

 

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Dr Adam Mark Hill

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£1.179

8,481

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Same as above

 

 

- Price

 

 

 

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

 

London stock exchange, AIM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Matthew Hall

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£117.9

1,272

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Same as above

 

 

- Price

 

 

 

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Ron Kirschner

2

 

Reason for the notification

 

a)

 

Position/status

General Counsel and Company Secretary

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

 

 

Identification code

ISIN: GB00BYQ94H38

 

 

b)

 

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price

Volume

 

 

 

£1.204

1,652

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

Same as above

 

 

- Price

 

 

 

e)

 

Date of the transaction 

4 June 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, General Counsel and Company Secretary

contact@oncimmune.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDELBBBQLEBBK
Date   Source Headline
1st Oct 20187:00 amRNSBusiness Update
28th Sep 20187:00 amRNSAppointment of Non-Executive Director
25th Sep 20183:45 pmRNSIASLC World Conference on Lung Cancer Presentation
25th Sep 20187:00 amRNSGrant of options
24th Sep 20187:00 amRNSBoard Change
13th Sep 20187:00 amRNSAppointment of Marco Casarin as General Manager
26th Jul 201812:33 pmRNSNotification & Public Disclosure of a Transaction
4th Jun 20187:38 amRNSBusiness Update
24th May 20187:00 amRNSNew Distribution Agreements for EarlyCDT®-Lung Kit
23rd May 20187:00 amRNSOncimmune Publishes Study in PLOS ONE
14th May 20187:00 amRNSOncimmune Launches EarlyCDT®-Liver Test in the US
23rd Apr 20187:00 amRNSPDMR Notification
11th Apr 20182:01 pmRNSHolding(s) in Company
27th Mar 20188:00 amRNSFinal tranche of £10m equity investment
27th Mar 20187:00 amRNSAppointment of Dr Adam Hill as CMO and CSO
13th Feb 20187:00 amRNSInterim Results for the half year ended 30 Nov 17
5th Feb 20187:01 amRNSUniversity of Nottingham share sale
5th Feb 20187:00 amRNSHoldings in Company
2nd Feb 20184:45 pmRNSTotal Voting Rights
29th Jan 20187:00 amRNSFirst tranche of £10m equity investment
23rd Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
22nd Jan 201811:21 amRNSResult of General Meeting
9th Jan 20187:00 amRNSAppointment of Non-Executive Director
4th Jan 20187:30 amRNSNotice of General Meeting
2nd Jan 20187:00 amRNSFramework agreement, licence and £10m investment
21st Dec 20177:00 amRNSValidation of EarlyCDT®-Liver test
30th Nov 20173:53 pmRNSHolding(s) in Company
29th Nov 20179:55 amRNSResult of AGM
27th Nov 20177:00 amRNSAppointment of joint brokers
24th Nov 20177:00 amRNSSatisfaction of Delayed Completion Placing
22nd Nov 20177:00 amRNSDeadline extended for Delayed Completion Placing
16th Nov 20177:00 amRNSDistribution agreement signed for Iran
9th Nov 20177:00 amRNSLaunch of "Finger Stick" Sample Collection
3rd Nov 20177:00 amRNSAnnual Report and Accounts and AGM Notification
27th Oct 201710:32 amRNSDirector/PDMR Shareholding
20th Oct 20177:00 amRNSResults for the year ended 31 May 2017
18th Oct 20177:00 amRNSDistribution Agreement in Poland
10th Oct 201711:15 amRNSHoldings in Company
10th Oct 20177:00 amRNSNotice of Results
27th Sep 20172:11 pmRNSSuccessful £5.0m placing
26th Sep 20175:12 pmRNSProposed placing to raise up to £5.3m
19th Sep 20177:00 amRNSEarlyCDT®-Lung Kit Distribution Agreements
18th Sep 20177:00 amRNSData presented at the 11th Annual ILCA
14th Sep 20177:00 amRNSBusiness Update
29th Aug 20177:00 amRNSOncimmune and Scancell Present Data
20th Jul 20171:59 pmRNSExercise of Options & 2007 Share Option Scheme
7th Jul 20177:00 amRNSHolding(s) in Company
5th Jun 20177:00 amRNSBusiness Update and New Distribution Agreements
31st May 20177:00 amRNSCE Mark for EarlyCDT-Lung Kit
17th May 20177:00 amRNSGRANT OF OPTIONS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.